MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$34,008K
EPS
-$0.49
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
28,996
20,687
26,281*
18,225
General and administrative
8,213
7,136
12,856*
6,871
Total operating expenses
37,209
27,823
39,137
25,096
Loss from operations
-37,209
-27,823
-39,137*
-25,096
Interest income
4,732
4,196
3,715*
4,948
Change in fair value of contingent value right liability
-
-
0*
0
Income tax expense
-
-
0*
0
Other expense
-8
0
-46*
0
Total other income (expense), net
4,724
4,196
3,669*
4,948
Net loss
-32,485
-23,627
-35,469*
-20,148
Net unrealized gaines on marketable securities
-1,523
-716
-76*
398
Comprehensive loss
-34,008
-24,343
-35,546
-19,750
Basic EPS
-0.49
-0.38
-0.637
-0.32
Diluted EPS
-0.49
-0.38
-0.637
-0.32
Basic Average Shares
66,171,581
62,799,326
55,793,831
62,093,795
Diluted Average Shares
66,171,581
62,799,326
55,793,831
62,093,795
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$34,008K
(-33.39%↓ Y/Y)
Interest income
$4,732K
(45.56%↑ Y/Y)
Net loss
-$32,485K
(-28.22%↓ Y/Y)
Net unrealized
gaines on marketable...
-$1,523K
(-845.96%↓ Y/Y)
Total other income
(expense), net
$4,724K
(45.40%↑ Y/Y)
Other expense
-$8K
(-300.00%↓ Y/Y)
Loss from operations
-$37,209K
(-30.17%↓ Y/Y)
Total operating
expenses
$37,209K
(30.17%↑ Y/Y)
Research and development
$28,996K
(34.92%↑ Y/Y)
General and
administrative
$8,213K
(15.79%↑ Y/Y)
Buy us a coffee
Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. (ELVN)